Senator Marco Rubio | Official U.S. House headshot
Senator Marco Rubio | Official U.S. House headshot
A U.S. Food and Drug Administration (FDA) advisory committee recently determined that phenylephrine, an ingredient commonly used to treat sinus and nasal congestion, is ineffective in treating these symptoms. This revelation has raised concerns about large pharmaceutical companies continuing to sell products containing phenylephrine while profiting from and deceiving sick Americans.
U.S. Senator Marco Rubio (R-FL) has taken action by sending letters to the manufacturing companies demanding answers. In these letters, he seeks to determine if these companies purposefully misled consumers to maintain profit margins. The letters were sent to Johnson & Johnson, Procter & Gamble, Reckitt Benckiser, Kenvue, and GSK, all manufacturers of common decongestant medicines that use phenylephrine.
Senator Rubio expressed his concerns, stating, "Millions of Americans have relied on your phenylephrine-based products to achieve relief. It is concerning that despite a multitude of evidence proving the inefficacy of this ingredient, your company has deceived sick Americans in pursuit of low manufacturing costs and high profit margins."
The FDA Non-prescription Drug Advisory Committee unanimously concluded earlier this month that current evidence does not show that orally administered phenylephrine, under the recommended dosage, is an effective nasal decongestant. This designation was initially given by the FDA in 1976 when drug approvals were subject to less stringent regulations. However, over time, the FDA has revised its safety and efficacy standards, yet never re-evaluated phenylephrine's efficacy with these updated standards. Despite this, hundreds of over-the-counter products containing oral phenylephrine are currently being sold.
Research questioning phenylephrine's effectiveness dates back to 2007, when scientists petitioned the FDA to review the data and remove the ingredient from the market. The studies used for initial approval were found to have significant flaws and biases and did not meet current FDA standards. Since 2016, three additional studies have further confirmed that phenylephrine is not effective when compared to a placebo.
Senator Rubio emphasized the importance of consumer trust in pharmaceutical companies and the FDA, stating, "Americans put their faith in pharmaceutical companies, and the FDA, to sell products that are both safe and effective in treating the symptoms listed on the packaging. It is concerning that the data proving phenylephrine's inefficacy has been present for so many years, yet companies have not adjusted their dosage or composition of their products."
To provide clarity and transparency, Senator Rubio has requested that the manufacturers answer several questions, including their reasons for including phenylephrine in their products, their awareness of the challenges to FDA approval, and their intentions regarding the use of phenylephrine in the future.
As the cold and flu season approaches, Senator Rubio believes it is crucial for Americans to receive answers about the products they have long trusted for relief. He expects prompt responses from the manufacturers and hopes to shed light on the issue of ineffective decongestants.
To read the full text of the letters sent to each manufacturer, click on the links below:
Alerts Sign-up